Conference Coverage

HRS: Cardiac device remote monitoring drops hospitalizations, costs

View on the News

New findings could boost remote monitoring

Data like those in Dr. Piccini’s report as well as the statement in May from the Heart Rhythm Society calling remote monitoring the standard of care (Heart Rhythm 2015 [doi.10.1016/j.hrthm.2015.05.008]) are very compelling. There has been a lag in the uptake of remote monitoring, but these new developments will make it impossible for administrators and payers to ignore remote monitoring any longer.

Mitchel L. Zoler/Frontline Medical News

Dr. Jonathan M. Kalman

What we need now is an infrastructure to provide remote monitoring to the millions of patients who have implanted cardiovascular devices. Adopting remote monitoring as the standard of care involves more than just a declaration. Monitoring programs need capable technicians who can collect and evaluate the data that come in. It’s a big commitment, but something for which the benefit clearly outweighs the cost. We keep patients in better health while seeing them less often.

Dr. Jonathan M. Kalman is professor and head of the heart rhythm department of Royal Melbourne Hospital, Australia. He has received research support from Boston Scientific, Medtronic, and St. Jude. He made these comments in an interview.


 

AT HEART RHYTHM 2015

References

The study findings highlight “a major opportunity for quality improvement,” Dr. Piccini concluded. “There is plenty of evidence to motivate physicians, health care systems, and payers” to embrace the new HRS recommendations on remote monitoring. But to be effective, each patient participating in remote monitoring must be educated about the process and be willing to take the steps necessary to make remote monitoring succeed, he added.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Pages

Recommended Reading

Statins, fibrates lower stroke risk in elderly
MDedge Internal Medicine
Ischemia a bigger concern than PE recurrence?
MDedge Internal Medicine
Larger-gauge PICCs, VTE history increase PICC-DVT risk
MDedge Internal Medicine
HRS: Meta-analyses strengthen obesity–atrial fib link
MDedge Internal Medicine
Warfarin bridge therapy ups bleeding risk, with no reduction in VTE
MDedge Internal Medicine
European Medicines Agency recommends evolocumab for cholesterol control
MDedge Internal Medicine
Newer oral contraceptives pose higher VTE risk
MDedge Internal Medicine
DDW: Postbleed blood thinners up rebleeding risk, lower death risk
MDedge Internal Medicine
EuroPCR: CT-derived FFR promising in evaluating chest pain
MDedge Internal Medicine
AUA: Testosterone may not deserve its reputation as a cardiovascular culprit
MDedge Internal Medicine

Related Articles